GCP
ALNA

GSA Capital Partners’s Allena Pharmaceuticals ALNA Stock Holding History

GSA Capital Partners’s Portfolio ALNA Stock Details ALNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-152,731
Closed -$138K – 1949
2021
Q3 		$138K Buy
+152,731
New +$150K 0.01% 1292

Other funds holding ALNA

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GSA Capital Partners's ALNA Position: Q4 2021 in Review

GSA Capital Partners sold out of Allena Pharmaceuticals (ALNA) in Q4 2021, closing a stake of 152,731 shares — an estimated $138K sold.

GSA Capital Partners first reported a position in ALNA in Q3 2021 and held it in 1 quarter. The position peaked at $138K in Q3 2021. 30 funds tracked by Wall St. Rank hold ALNA as of Q4 2021.

  • GSA Capital Partners reported no remaining Allena Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • GSA Capital Partners sold 152,731 Allena Pharmaceuticals shares in Q4 2021, an estimated $138K.
  • GSA Capital Partners first reported a position in Allena Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • GSA Capital Partners's Allena Pharmaceuticals position peaked at $138K in Q3 2021.
  • 30 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q4 2021.

Based on GSA Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.